Profiles

Keywords
Last Name
Institution

Connection

John Somberg to Humans

This is a "connection" page, showing publications John Somberg has written about Humans.

 
Connection Strength
 
 
 
3.850
 
  1. Somberg J, Molnar J. Evaluating Serious Adverse Drug Reactions. Cardiology. 2018; 139(3):202.
    View in: PubMed
    Score: 0.047
  2. Somberg J, Molnar J. Adverse Reactions of Amiodarone on the Thyroid. Cardiology. 2016; 134(3):364-5.
    View in: PubMed
    Score: 0.041
  3. Somberg J. Angiotensin-Neprilysin Combinations Marketing Poly or Therapeutic Optimization. Am J Ther. 2015 Sep-Oct; 22(5):321.
    View in: PubMed
    Score: 0.039
  4. Somberg JC, Molnar J. Retrospective Evaluation on the Analgesic Activities of 2 Compounded Topical Creams and Voltaren Gel in Chronic Noncancer Pain. Am J Ther. 2015 Sep-Oct; 22(5):342-9.
    View in: PubMed
    Score: 0.039
  5. Molnar J, Somberg JC. Evaluation of the Effects of Different Energy Drinks and Coffee on Endothelial Function. Am J Cardiol. 2015 Nov 01; 116(9):1457-60.
    View in: PubMed
    Score: 0.039
  6. Somberg J. The Need for Stimulation. Am J Ther. 2015 Jul-Aug; 22(4):243.
    View in: PubMed
    Score: 0.039
  7. Molnar J, Somberg JC. A Rapid Method to Evaluate Cardiac Repolarization Changes: The Effect of Two Coffee Strengths on the QT Interval. Cardiology. 2015; 131(3):203-8.
    View in: PubMed
    Score: 0.039
  8. Somberg JC, Molnar J. Retrospective Study on the Analgesic Activity of a Topical (TT-CTAC) Cream in Patients With Diabetic Neuropathy and Other Chronic Pain Conditions. Am J Ther. 2015 May-Jun; 22(3):214-21.
    View in: PubMed
    Score: 0.038
  9. Somberg J, Molnar J. Lesson to be learned from the renal denervation trials. Am J Ther. 2015 May-Jun; 22(3):167-70.
    View in: PubMed
    Score: 0.038
  10. Somberg J. Computerization in medicine. Am J Ther. 2015 Mar-Apr; 22(2):89.
    View in: PubMed
    Score: 0.038
  11. Somberg JC. The new year. Am J Ther. 2015 Jan-Feb; 22(1):1.
    View in: PubMed
    Score: 0.038
  12. Somberg JC. The failing Ebola policy. Am J Ther. 2014 Nov-Dec; 21(6):441.
    View in: PubMed
    Score: 0.037
  13. Somberg JC. Digoxin therapy for atrial fibrillation in the twenty-first century. Am J Ther. 2014 Sep-Oct; 21(5):325-6.
    View in: PubMed
    Score: 0.037
  14. Somberg J. OUS results, clinical studies and therapeutic innovation in America. Am J Ther. 2014 Jul-Aug; 21(4):233.
    View in: PubMed
    Score: 0.036
  15. Somberg J. International vs. hospital acquired infection. Am J Ther. 2014 May-Jun; 21(3):141.
    View in: PubMed
    Score: 0.036
  16. Somberg J. Courts, patents, litigation & patient care. Am J Ther. 2014 May-Jun; 21(3):142.
    View in: PubMed
    Score: 0.036
  17. Somberg JC, McEwen P, Molnar J. Assessment of cardiovascular and noncardiovascular medical device recalls. Am J Cardiol. 2014 Jun 01; 113(11):1899-903.
    View in: PubMed
    Score: 0.036
  18. Somberg J. Clinical trials and their surprises. Am J Ther. 2014 Mar-Apr; 21(2):67.
    View in: PubMed
    Score: 0.035
  19. Somberg JC. Guidelines for a new year. Am J Ther. 2014 Jan-Feb; 21(1):1.
    View in: PubMed
    Score: 0.035
  20. Somberg J. The conflict of interest charade. Am J Ther. 2013 Nov-Dec; 20(6):591.
    View in: PubMed
    Score: 0.035
  21. Somberg J. Health care in turmoil. Am J Ther. 2013 Sep-Oct; 20(5):459.
    View in: PubMed
    Score: 0.034
  22. Somberg J. The Supremes got it right. Am J Ther. 2013 Jul-Aug; 20(4):315.
    View in: PubMed
    Score: 0.034
  23. Somberg J, Molnar J. The dark side of implantable cardioverter defibrillator therapy. Cardiology. 2013; 124(4):213-5.
    View in: PubMed
    Score: 0.033
  24. Somberg JC. The cart before the horse. Am J Ther. 2013 Mar-Apr; 20(2):127.
    View in: PubMed
    Score: 0.033
  25. Somberg JC. Proposed accelerated FDA approvals for special medical use. Am J Ther. 2012 Nov; 19(6):393-4.
    View in: PubMed
    Score: 0.032
  26. Somberg JC. Making America more competitive: a paradigm shift in drug and device development. Am J Ther. 2012 Sep; 19(5):315-6.
    View in: PubMed
    Score: 0.032
  27. Somberg JC. The human microbiome and therapeutics. Am J Ther. 2012 Jul; 19(4):247.
    View in: PubMed
    Score: 0.032
  28. Somberg J. Is there an imperative for generic profiling to hasten the age of personalized medicine. Am J Ther. 2012 May; 19(3):163.
    View in: PubMed
    Score: 0.031
  29. Somberg JC. Drug shortages and ensuring the U.S. supply of needed pharmaceuticals. Am J Ther. 2012 Mar; 19(2):65.
    View in: PubMed
    Score: 0.031
  30. Somberg J. Guidelines or 10 commandments. Am J Ther. 2012 Jan; 19(1):1.
    View in: PubMed
    Score: 0.031
  31. Somberg J. Drug and device trials: should we ask more. Am J Ther. 2011 Nov; 18(6):435.
    View in: PubMed
    Score: 0.030
  32. Somberg JC. The impact of comorbidities on stroke prophylaxis strategies in atrial fibrillation patients. Am J Ther. 2011 Nov; 18(6):510-7.
    View in: PubMed
    Score: 0.030
  33. Somberg JC. The device development pinata. Am J Ther. 2011 Sep; 18(5):339.
    View in: PubMed
    Score: 0.030
  34. Somberg JC. Are we facilitating therapeutic innovation? Am J Ther. 2011 Jul; 18(4):279.
    View in: PubMed
    Score: 0.029
  35. Somberg JC. Has the food and drug administration changed the drug approval process? Am J Ther. 2011 May; 18(3):179.
    View in: PubMed
    Score: 0.029
  36. Somberg JC, Preston RA, Ranade V, Cvetanovic I, Molnar J. Gender differences in cardiac repolarization following intravenous sotalol administration. J Cardiovasc Pharmacol Ther. 2012 Mar; 17(1):86-92.
    View in: PubMed
    Score: 0.029
  37. Somberg JC. Inappropriate attack on device development. Am J Ther. 2011 Mar-Apr; 18(2):91.
    View in: PubMed
    Score: 0.029
  38. Somberg JC. Have we maxed out on new therapies. Am J Ther. 2011 Mar-Apr; 18(2):91.
    View in: PubMed
    Score: 0.029
  39. Somberg JC. From therapeutic nihilism to therapeutic success. Am J Ther. 2011 Jan; 18(1):1.
    View in: PubMed
    Score: 0.028
  40. Somberg JC. The Food and Drug Administration's paternalism. Am J Ther. 2010 Nov-Dec; 17(6):533-4.
    View in: PubMed
    Score: 0.028
  41. Somberg JC. The midodrine withdrawal. Am J Ther. 2010 Sep-Oct; 17(5):445.
    View in: PubMed
    Score: 0.028
  42. Somberg JC, Preston RA, Ranade V, Molnar J. QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol. Cardiology. 2010; 116(3):219-25.
    View in: PubMed
    Score: 0.028
  43. Somberg JC, Preston RA, Ranade V, Molnar J. Developing a safe intravenous sotalol dosing regimen. Am J Ther. 2010 Jul-Aug; 17(4):365-72.
    View in: PubMed
    Score: 0.027
  44. Somberg J. Device safety and effectiveness. Am J Ther. 2010 Jul-Aug; 17(4):357.
    View in: PubMed
    Score: 0.027
  45. Somberg J. Composite end points, black box warnings, and allegations of bias. Am J Ther. 2010 May-Jun; 17(3):233.
    View in: PubMed
    Score: 0.027
  46. Somberg J, Cherubini A, Lowenthal DT, Paran E, Mecocci P, Williams LS, Senin U, Hahr AJ, Molitch ME, Cheng JW, Frishman WH, Aronow WS. Topics in clinical pharmacology: cardiovascular and diabetes mellitus. Dis Mon. 2010 Mar; 56(3):105-79.
    View in: PubMed
    Score: 0.027
  47. Somberg JC. Is the device development process adequate. Am J Ther. 2010 Mar-Apr; 17(2):123-4.
    View in: PubMed
    Score: 0.027
  48. Somberg JC. The hubris of science: defending the scientific process from political agendas. Am J Ther. 2010 Jan-Feb; 17(1):1.
    View in: PubMed
    Score: 0.027
  49. Somberg JC. New advances and new questions in cardiovascular therapeutics. Am J Ther. 2009 Sep-Oct; 16(5):375-7.
    View in: PubMed
    Score: 0.026
  50. Somberg JC. Medical isotope shortages. Am J Ther. 2009 Sep-Oct; 16(5):378.
    View in: PubMed
    Score: 0.026
  51. Somberg J. Health care reform. Am J Ther. 2009 Jul-Aug; 16(4):281-2.
    View in: PubMed
    Score: 0.026
  52. Somberg J. Supporting therapeutic innovation. Am J Ther. 2009 May-Jun; 16(3):203.
    View in: PubMed
    Score: 0.025
  53. Molnar J, Somberg JC. Neurocardiogenic syncope. Cardiology. 2009; 114(1):47-9.
    View in: PubMed
    Score: 0.025
  54. Somberg JC. The extrapolation of study results in the device approval process. Am J Cardiol. 2009 May 01; 103(9):1323-4.
    View in: PubMed
    Score: 0.025
  55. Molnar J, Somberg JC. The dynamics of QT dispersion. Cardiology. 2009; 113(3):169-71.
    View in: PubMed
    Score: 0.025
  56. Somberg JC. Evidence based or mechanism based therapeutics. Am J Ther. 2009 Jan-Feb; 16(1):1.
    View in: PubMed
    Score: 0.025
  57. Somberg JC, Molnar J. The management of acute heart failure and diuretic therapy. Am J Ther. 2009 Jan-Feb; 16(1):93-7.
    View in: PubMed
    Score: 0.025
  58. Somberg JC, Molnar J. The pleiotropic effects of ethacrynic acid. Am J Ther. 2009 Jan-Feb; 16(1):102-4.
    View in: PubMed
    Score: 0.025
  59. Somberg JC, Molnar J. Therapeutic approaches to the treatment of edema and ascites: the use of diuretics. Am J Ther. 2009 Jan-Feb; 16(1):98-101.
    View in: PubMed
    Score: 0.025
  60. Molnar J, Somberg JC. The clinical pharmacology of ethacrynic acid. Am J Ther. 2009 Jan-Feb; 16(1):86-92.
    View in: PubMed
    Score: 0.025
  61. Lin C, Somberg T, Molnar J, Somberg J. The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology. 2009; 113(1):59-65.
    View in: PubMed
    Score: 0.025
  62. Somberg J. The drug eluting stent challenge. Am J Ther. 2008 Nov-Dec; 15(6):505.
    View in: PubMed
    Score: 0.025
  63. Somberg J. Licensing to prescribe. Am J Ther. 2008 Sep-Oct; 15(5):417-8.
    View in: PubMed
    Score: 0.024
  64. Molnar J, Somberg JC. QT dispersion: still a useful measurement. Cardiology. 2009; 112(3):165-7.
    View in: PubMed
    Score: 0.024
  65. Somberg JC. The sins of ghostwriting. Am J Ther. 2008 Jul-Aug; 15(4):297-8.
    View in: PubMed
    Score: 0.024
  66. Nada A, Baxter S, Loraas E, Somberg JC. Incidence and predictors of screen failures due to positive urine tests for alcohol, drugs of abuse, and cotinine among normal healthy research volunteers (NHRVs): analysis of data from 687 NHRVs screened at a large clinical pharmacology unit in the United States. Am J Ther. 2008 May-Jun; 15(3):214-20.
    View in: PubMed
    Score: 0.024
  67. Somberg JC, Molnar J. The cholesterol hypothesis: questioned? Am J Ther. 2008 May-Jun; 15(3):292-5.
    View in: PubMed
    Score: 0.024
  68. Somberg J, Molnar J. Ventricular repolarization spectra. Cardiology. 2008; 111(3):207-8.
    View in: PubMed
    Score: 0.024
  69. Somberg JC. Flecainide: safety and efficacy. Cardiology. 2008; 111(2):82.
    View in: PubMed
    Score: 0.024
  70. Somberg J. FDA user fees and innovation. Am J Ther. 2008 Mar-Apr; 15(2):97.
    View in: PubMed
    Score: 0.023
  71. Somberg J. Therapeutic hangups. Am J Ther. 2008 Jan-Feb; 15(1):1.
    View in: PubMed
    Score: 0.023
  72. Nada A, Somberg J. First-in-Man (FIM) clinical trials post-TeGenero: a review of the impact of the TeGenero trial on the design, conduct, and ethics of FIM trials. Am J Ther. 2007 Nov-Dec; 14(6):594-604.
    View in: PubMed
    Score: 0.023
  73. Somberg J. Screening drugs for QT prolongation. Am J Ther. 2007 Sep-Oct; 14(5):419-20.
    View in: PubMed
    Score: 0.023
  74. Somberg J. Mandatory post marketing studies. Am J Ther. 2007 Jul-Aug; 14(4):321.
    View in: PubMed
    Score: 0.022
  75. Somberg J. Patent foramen ovale closure devices: thoughts from the circulatory device advisory panel. Am J Cardiol. 2007 Sep 01; 100(5):905-6.
    View in: PubMed
    Score: 0.022
  76. Somberg J. Guilt by association. Am J Ther. 2007 May-Jun; 14(3):229-30.
    View in: PubMed
    Score: 0.022
  77. Somberg J. Biologic generics. Am J Ther. 2007 May-Jun; 14(3):230.
    View in: PubMed
    Score: 0.022
  78. Somberg J. The drug safety review process. Am J Ther. 2007 Mar-Apr; 14(2):119.
    View in: PubMed
    Score: 0.022
  79. Somberg J, Weinberger J. Late stent thrombosis: problem or not? Am J Cardiol. 2007 Apr 01; 99(7):1020-3.
    View in: PubMed
    Score: 0.022
  80. Somberg J. The report of the Institute of Medicine on drug safety. Am J Ther. 2007 Jan-Feb; 14(1):1-2.
    View in: PubMed
    Score: 0.022
  81. Somberg J. The hypertension peril and drug development. Am J Ther. 2007 Jan-Feb; 14(1):2.
    View in: PubMed
    Score: 0.022
  82. Cvetanovic I, Ranade V, Molnar J, Whelton A, Somberg J. The evaluation of the diuretic action of parenteral formulations of metolazone. Am J Ther. 2007 Jan-Feb; 14(1):25-9.
    View in: PubMed
    Score: 0.022
  83. Somberg J. Physician specific prescribing information. Am J Ther. 2006 Nov-Dec; 13(6):465.
    View in: PubMed
    Score: 0.021
  84. Somberg J. Surrogate endpoints and drug approval. Am J Ther. 2006 Sep-Oct; 13(5):388.
    View in: PubMed
    Score: 0.021
  85. Somberg J. Genetic drug targeting. Am J Ther. 2006 Jul-Aug; 13(4):289-90.
    View in: PubMed
    Score: 0.021
  86. Molnar J, Ranade V, Cvetanovic I, Molnar Z, Somberg JC. Evaluation of a 12-lead digital Holter system for 24-hour QT interval assessment. Cardiology. 2006; 106(4):224-32.
    View in: PubMed
    Score: 0.021
  87. Somberg JC. Risk assessment, drug approval, and liability. Am J Ther. 2006 May-Jun; 13(3):181-2.
    View in: PubMed
    Score: 0.021
  88. Somberg JC. Pharmaceutical companies and medical therapeutics education. Am J Ther. 2006 Mar-Apr; 13(2):93.
    View in: PubMed
    Score: 0.020
  89. Somberg J, Molnar J. Letter from Konstantinos P. Letsas et al. - invited editorial comment. Cardiology. 2006; 105(3):148.
    View in: PubMed
    Score: 0.020
  90. Somberg JC. Nesiritide: the wrong controversy. Am J Ther. 2005 Sep-Oct; 12(5):377-8.
    View in: PubMed
    Score: 0.020
  91. Ranade VV, Somberg JC. Chiral cardiovascular drugs: an overview. Am J Ther. 2005 Sep-Oct; 12(5):439-59.
    View in: PubMed
    Score: 0.020
  92. Lin C, Cvetanovic I, Ke X, Ranade V, Somberg J. A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and hypokalemia on the blockade of human ether-a-go-go-related gene (HERG) channels. Am J Ther. 2005 Jul-Aug; 12(4):328-36.
    View in: PubMed
    Score: 0.019
  93. Somberg JC. The new drug evaluation process: risk benefit ratio. Am J Ther. 2005 May-Jun; 12(3):199-200.
    View in: PubMed
    Score: 0.019
  94. Somberg J. Lessons learned from the COX-2 advisory hearings. Am J Ther. 2005 Mar-Apr; 12(2):105.
    View in: PubMed
    Score: 0.019
  95. Lin C, Ke X, Cvetanovic I, Ranade V, Somberg J. The influence of extracellular acidosis on the effect of IKr blockers. J Cardiovasc Pharmacol Ther. 2005 Mar; 10(1):67-76.
    View in: PubMed
    Score: 0.019
  96. Somberg J. The politics of therapeutics. Am J Ther. 2004 Nov-Dec; 11(6):422.
    View in: PubMed
    Score: 0.019
  97. Somberg JC, Molnar J. The pharmacologic treatment of heart failure. Am J Ther. 2004 Nov-Dec; 11(6):480-8.
    View in: PubMed
    Score: 0.019
  98. Somberg J. Drug trial registries. Am J Ther. 2004 Sep-Oct; 11(5):327.
    View in: PubMed
    Score: 0.018
  99. Somberg J. Obesity therapeutics in the shadows: editorial. Am J Ther. 2004 May-Jun; 11(3):155.
    View in: PubMed
    Score: 0.018
  100. Somberg JC, Timar S, Bailin SJ, Lakatos F, Haffajee CI, Tarjan J, Paladino WP, Sarosi I, Kerin NZ, Borbola J, Bridges DE, Molnar J. Lack of a hypotensive effect with rapid administration of a new aqueous formulation of intravenous amiodarone. Am J Cardiol. 2004 Mar 01; 93(5):576-81.
    View in: PubMed
    Score: 0.018
  101. Somberg J. Should statins go OTC. Am J Ther. 2004 Jan-Feb; 11(1):1-2.
    View in: PubMed
    Score: 0.018
  102. Somberg JC, Torres V, Keren G, Butler B, Tepper D, Kleinbaum H, Molnar J. Enhancement of myocardial vulnerability by atrial fibrillation. Am J Ther. 2004 Jan-Feb; 11(1):33-43.
    View in: PubMed
    Score: 0.018
  103. Cobleigh M, Somberg JC. A case of herceptin cardiotoxicity. Am J Ther. 2004 Jan-Feb; 11(1):74-6.
    View in: PubMed
    Score: 0.018
  104. Somberg J. Therapeutics, drug pricing and innovation. Am J Ther. 2003 Nov-Dec; 10(6):381.
    View in: PubMed
    Score: 0.017
  105. Somberg JC, Molnar J. The quest for an aqueous amiodarone. Am J Ther. 2003 Nov-Dec; 10(6):458-61.
    View in: PubMed
    Score: 0.017
  106. Somberg J. Clinical trials registries. Am J Ther. 2003 Sep-Oct; 10(5):309-10.
    View in: PubMed
    Score: 0.017
  107. Somberg J. Biomarker and surrogate endpoints. Am J Ther. 2003 Jul-Aug; 10(4):239-40.
    View in: PubMed
    Score: 0.017
  108. Somberg JC. SARS challenges therapeutics. Am J Ther. 2003 May-Jun; 10(3):161.
    View in: PubMed
    Score: 0.017
  109. Somberg JC. Hypertension therapeutics in turmoil. Am J Ther. 2003 Mar-Apr; 10(2):81-2.
    View in: PubMed
    Score: 0.017
  110. Somberg JC. Free exchange of ideas. Am J Ther. 2003 Jan-Feb; 10(1):1.
    View in: PubMed
    Score: 0.016
  111. Somberg JC. Pediatric drug development. Am J Ther. 2003 Jan-Feb; 10(1):2.
    View in: PubMed
    Score: 0.016
  112. Somberg JC. Clinical therapeutic conference. Am J Ther. 2003 Jan-Feb; 10(1):78-80.
    View in: PubMed
    Score: 0.016
  113. Najeed SA, Khan IA, Molnar J, Somberg JC. Differential effect of glyburide (glibenclamide) and metformin on QT dispersion: a potential adenosine triphosphate sensitive K+ channel effect. Am J Cardiol. 2002 Nov 15; 90(10):1103-6.
    View in: PubMed
    Score: 0.016
  114. Gallik DM, Singer I, Meissner MD, Molnar J, Somberg JC. Hemodynamic and surface electrocardiographic effects of a new aqueous formulation of intravenous amiodarone. Am J Cardiol. 2002 Nov 01; 90(9):964-8.
    View in: PubMed
    Score: 0.016
  115. Somberg JC. Arrhythmia therapy. Am J Ther. 2002 Nov-Dec; 9(6):537-42.
    View in: PubMed
    Score: 0.016
  116. Somberg JC, Bailin SJ, Haffajee CI, Paladino WP, Kerin NZ, Bridges D, Timar S, Molnar J. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am J Cardiol. 2002 Oct 15; 90(8):853-9.
    View in: PubMed
    Score: 0.016
  117. Somberg JC. Restricting physician prescribing. Am J Ther. 2002 Sep-Oct; 9(5):369.
    View in: PubMed
    Score: 0.016
  118. Somberg JC. Genetic polymorphisms. Am J Ther. 2002 Jul-Aug; 9(4):271.
    View in: PubMed
    Score: 0.016
  119. Somberg JC. Old drugs, new bottles, therapeutic advantage? Am J Ther. 2002 Jul-Aug; 9(4):273-4.
    View in: PubMed
    Score: 0.016
  120. Somberg JC. Clinical research oversight. Am J Ther. 2002 Mar-Apr; 9(2):85.
    View in: PubMed
    Score: 0.015
  121. Somberg JC. The generic conundrum. Am J Ther. 2002 Mar-Apr; 9(2):87-8.
    View in: PubMed
    Score: 0.015
  122. Somberg JC, Molnar J. Usefulness of QT dispersion as an electrocardiographically derived index. Am J Cardiol. 2002 Feb 01; 89(3):291-4.
    View in: PubMed
    Score: 0.015
  123. Somberg JC. Bioterrorism 2002. Am J Ther. 2002 Jan-Feb; 9(1):3.
    View in: PubMed
    Score: 0.015
  124. Ranade V, Somberg JC. Rapid determination of partition coefficients between n-octanol/water for cardiovascular therapies. Am J Ther. 2002 Jan-Feb; 9(1):19-24.
    View in: PubMed
    Score: 0.015
  125. Somberg J, Molnar J. Atrial fibrillation and valve disease. Adv Cardiol. 2002; 39:39-48.
    View in: PubMed
    Score: 0.015
  126. Somberg JC. A challenge to America. Am J Ther. 2001 Nov-Dec; 8(6):383.
    View in: PubMed
    Score: 0.015
  127. Somberg JC. A new therapeutic millennium [correction of millenium]. Am J Ther. 2001 Nov-Dec; 8(6):385-6.
    View in: PubMed
    Score: 0.015
  128. Somberg JC. Stem-cell research. Am J Ther. 2001 Sep-Oct; 8(5):307.
    View in: PubMed
    Score: 0.015
  129. Ranade VV, Somberg JC. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am J Ther. 2001 Sep-Oct; 8(5):345-57.
    View in: PubMed
    Score: 0.015
  130. Somberg JC. Class effects of pharmaceuticals and therapeutic interchangeability. Am J Ther. 2001 Jul-Aug; 8(4):221-2.
    View in: PubMed
    Score: 0.015
  131. Somberg JC. Do we need to accredit clinical research? Am J Ther. 2001 Jul-Aug; 8(4):223-4.
    View in: PubMed
    Score: 0.015
  132. Somberg JC. Proposed product labeling changes: does it really matter? Am J Ther. 2001 May-Jun; 8(3):145-6.
    View in: PubMed
    Score: 0.015
  133. Somberg JC. Pediatric exclusivity and genericizing pharmaceuticals. Am J Ther. 2001 Mar-Apr; 8(2):79-80.
    View in: PubMed
    Score: 0.014
  134. Yelamanchi VP, Molnar J, Ranade V, Somberg JC. Influence of electrolyte abnormalities on interlead variability of ventricular repolarization times in 12-lead electrocardiography. Am J Ther. 2001 Mar-Apr; 8(2):117-22.
    View in: PubMed
    Score: 0.014
  135. Somberg JC. Are we overregulated? Am J Ther. 2001 Jan-Feb; 8(1):1-2.
    View in: PubMed
    Score: 0.014
  136. Somberg JC. Clinical therapeutic conference: congestive heart failure therapy. Am J Ther. 2001 Jan-Feb; 8(1):65-72.
    View in: PubMed
    Score: 0.014
  137. Somberg JC. The cost of therapy. Am J Ther. 2000 Nov; 7(6):343-4.
    View in: PubMed
    Score: 0.014
  138. Somberg JC. Sudden death in athletes. Am J Ther. 2000 Nov; 7(6):399-403.
    View in: PubMed
    Score: 0.014
  139. Somberg JC. A choice, not an echo. Am J Ther. 2000 Sep; 7(5):281.
    View in: PubMed
    Score: 0.014
  140. Somberg JC. Is clinical research oversight adequate in the United States? Am J Ther. 2000 Sep; 7(5):283-4.
    View in: PubMed
    Score: 0.014
  141. Clark CT, Resenblatt R, Somberg JC. Neurocardiogenic syncope with Addison's disease. Am J Ther. 2000 Sep; 7(5):328-31.
    View in: PubMed
    Score: 0.014
  142. Somberg JC. Is the evidence right in evidence-based practice? Am J Ther. 2000 May; 7(3):149-50.
    View in: PubMed
    Score: 0.014
  143. Somberg JC. What's gone wrong with clinical research. Am J Ther. 2000 Mar; 7(2):49-50.
    View in: PubMed
    Score: 0.013
  144. Somberg JC. A federal solution a regulation for all. Am J Ther. 2000 Jan; 7(1):1-2.
    View in: PubMed
    Score: 0.013
  145. Somberg JC. Medical judgment and therapeutics. Am J Ther. 1999 Nov; 6(6):291-2.
    View in: PubMed
    Score: 0.013
  146. Somberg JC. Reorganizing the flow of scientific information: is the age of electronic journalism here? Am J Ther. 1999 Sep; 6(5):235-6.
    View in: PubMed
    Score: 0.013
  147. Ranade V, Molnar J, Khokher T, Agarwal A, Mosnaim A, Somberg JC. Effect of angiotensin-converting enzyme therapy on QT interval dispersion. Am J Ther. 1999 Sep; 6(5):257-61.
    View in: PubMed
    Score: 0.013
  148. Somberg JC. International symposium on drug development. Am J Ther. 1999 Sep; 6(5):289.
    View in: PubMed
    Score: 0.013
  149. Somberg JC. Biomarkers and surrogate endpoints. Am J Ther. 1999 Jul; 6(4):179-80.
    View in: PubMed
    Score: 0.013
  150. Somberg JC, Borer JS. Advances in cardiovascular pharmacology: protocol design and methodology--the US regulatory process. Am J Ther. 1999 May; 6(3):175-8.
    View in: PubMed
    Score: 0.013
  151. Somberg JC. Reactions to prescribed drugs kill thousands annually. Am J Ther. 1998 May; 5(3):133.
    View in: PubMed
    Score: 0.012
  152. Tarabey R, Sukenik D, Molnar J, Somberg JC. Effect of intracoronary balloon inflation at percutaneous transluminal coronary angioplasty on QT dispersion. Am Heart J. 1998 Mar; 135(3):519-22.
    View in: PubMed
    Score: 0.012
  153. Somberg JC, Yelamanchi V, Molnar J, Aschermann M, Bernink PJ, Caspi A, Marmor A, Rabinowitz B, Reisin L, Ruzyllo W. Prostaglandin E1 : electrophysiological safety in patients with congestive heart failure and peripheral arterial occlusive disease. The Alprostadil Investigators. Am J Ther. 1997 Nov-Dec; 4(11-12):401-4.
    View in: PubMed
    Score: 0.011
  154. Molnar J, Rosenthal JE, Weiss JS, Somberg JC. QT interval dispersion in healthy subjects and survivors of sudden cardiac death: circadian variation in a twenty-four-hour assessment. Am J Cardiol. 1997 May 01; 79(9):1190-3.
    View in: PubMed
    Score: 0.011
  155. Ichkhan K, Molnar J, Somberg J. Relation of left ventricular mass and QT dispersion in patients with systematic hypertension. Am J Cardiol. 1997 Feb 15; 79(4):508-11.
    View in: PubMed
    Score: 0.011
  156. Milan DJ, Saul JP, Somberg JC, Molnar J. Efficacy of Intravenous and Oral Sotalol in Pharmacologic Conversion of Atrial Fibrillation: A Systematic Review and Meta-Analysis. Cardiology. 2017; 136(1):52-60.
    View in: PubMed
    Score: 0.011
  157. Khosla S, Duggal C, Somberg JC. Successful heart failure therapy is effective antiarrhythmia therapy. Am Heart J. 1996 May; 131(5):1048-50.
    View in: PubMed
    Score: 0.010
  158. Khosla S, Coutinho NB, Megellas MM, Mukherjee D, Somberg JC. Can nitroglycerin convert effort-induced angina in men into silent myocardial ischemia? Am J Cardiol. 1995 Aug 15; 76(5):337-9.
    View in: PubMed
    Score: 0.010
  159. Kerin NZ, Somberg J. Proarrhythmia: definition, risk factors, causes, treatment, and controversies. Am Heart J. 1994 Sep; 128(3):575-85.
    View in: PubMed
    Score: 0.009
  160. Somberg J, Shroff G, Khosla S, Ehrenpreis S. The clinical implications of first-pass metabolism: treatment strategies for the 1990s. J Clin Pharmacol. 1993 Jul; 33(7):670-3.
    View in: PubMed
    Score: 0.008
  161. Tullo NG, Landau S, Goldman I, Coutinho N, Somberg J. A randomized comparative study of the electrophysiological and electrocardiographic effects of isradipine vs verapamil. Acta Anaesthesiol Scand Suppl. 1993; 99:43-7.
    View in: PubMed
    Score: 0.008
  162. Somberg JC. Sharing regulatory review costs. J Clin Pharmacol. 1992 Oct; 32(10):867.
    View in: PubMed
    Score: 0.008
  163. Lavie E, Gergans G, Somberg JC. A comparison of tablets with oral suspension formulation of dipyridamole in thallium myocardial imaging. J Clin Pharmacol. 1992 Jun; 32(6):546-52.
    View in: PubMed
    Score: 0.008
  164. Freedman MD, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol. 1991 Nov; 31(11):1061-9.
    View in: PubMed
    Score: 0.008
  165. Somberg J, Kreamer J, Camba N. Amiodarone therapy guided by electrophysiologic testing: an update. J Clin Pharmacol. 1991 Nov; 31(11):1089-95.
    View in: PubMed
    Score: 0.008
  166. Kreamer JW, Zevitz M, Somberg JC. The role of electrophysiologic testing in the selection of amiodarone therapy. J Clin Pharmacol. 1989 May; 29(5):429-35.
    View in: PubMed
    Score: 0.006
  167. Somberg JC. Usefulness of electrophysiologic studies in predicting drug efficacy in patients receiving amiodarone. Am J Cardiol. 1987 Nov 15; 60(14):1218.
    View in: PubMed
    Score: 0.006
  168. Somberg JC, Zanger D, Levine E, Tepper D. Encainide: a new and potent antiarrhythmic. Am Heart J. 1987 Oct; 114(4 Pt 1):826-35.
    View in: PubMed
    Score: 0.006
  169. Schwartz J, Crocker K, Wynn J, Somberg JC. The antiarrhythmic effects of d-sotalol. Am Heart J. 1987 Sep; 114(3):539-44.
    View in: PubMed
    Score: 0.006
  170. Zempol P, Aogaichi K, Butler B, Tepper D, Somberg JC. Evaluation of dosing interval and optimum dose of cibenzoline. J Clin Pharmacol. 1987 Sep; 27(9):666-72.
    View in: PubMed
    Score: 0.006
  171. Somberg JC, Tepper D, Sacher H, Schwarz J. Chronic flecainide therapy selected by electrophysiology testing of intravenous flecainide. Am Heart J. 1987 Jul; 114(1 Pt 1):18-25.
    View in: PubMed
    Score: 0.006
  172. Miura DS, Schwartz J, Laux B, Wynn J, Keefe D, Somberg JC. Comparative efficacy of pirmenol and procainamide in a drug-resistant population with ventricular tachycardia. J Clin Pharmacol. 1987 Jul; 27(7):481-6.
    View in: PubMed
    Score: 0.006
  173. Wynn J, Fingerhood M, Keefe D, Maza S, Miura D, Somberg JC. Refractory ventricular tachycardia with flecainide. Am Heart J. 1986 Jul; 112(1):174-5.
    View in: PubMed
    Score: 0.005
  174. Somberg JC, Miura D, Keefe DL. The treatment of ventricular rhythm disturbances. Am Heart J. 1986 Jun; 111(6):1162-76.
    View in: PubMed
    Score: 0.005
  175. Keefe DL, Miura D, Somberg JC. Supraventricular tachyarrhythmias: their evaluation and therapy. Am Heart J. 1986 Jun; 111(6):1150-61.
    View in: PubMed
    Score: 0.005
  176. Miura DS, Wynn J, Torres V, Laux B, Keefe D, Somberg JC. Antiarrhythmic efficacy of ethmozine in patients with ventricular tachycardia as determined by programmed electrical stimulation. Am Heart J. 1986 Apr; 111(4):661-6.
    View in: PubMed
    Score: 0.005
  177. Wynn J, Torres V, Flowers D, Mizruchi M, Keefe D, Miura D, Somberg J. Antiarrhythmic drug efficacy at electrophysiology testing: predictive effectiveness of procainamide and flecainide. Am Heart J. 1986 Apr; 111(4):632-8.
    View in: PubMed
    Score: 0.005
  178. Somberg JC, Laux B, Wynn J, Keefe D, Miura DS. Lorcainide therapy in a cardiac arrest population. Am Heart J. 1986 Apr; 111(4):648-53.
    View in: PubMed
    Score: 0.005
  179. Keefe DL, Williams S, Torres V, Flowers D, Somberg JC. Prophylactic tocainide or lidocaine in acute myocardial infarction. Am J Cardiol. 1986 Mar 01; 57(8):527-31.
    View in: PubMed
    Score: 0.005
  180. Torres V, Tepper D, Flowers D, Wynn J, Lam S, Keefe D, Miura DS, Somberg JC. QT prolongation and the antiarrhythmic efficacy of amiodarone. J Am Coll Cardiol. 1986 Jan; 7(1):142-7.
    View in: PubMed
    Score: 0.005
  181. Wynn J, Miura DS, Torres V, Flowers D, Keefe D, Williams S, Somberg JC. Electrophysiologic evaluation of the antiarrhythmic effects of N-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease. Am J Cardiol. 1985 Nov 15; 56(13):877-81.
    View in: PubMed
    Score: 0.005
  182. Torres V, Flowers D, Somberg J. The clinical significance of polymorphic ventricular tachycardia provoked at electrophysiologic testing. Am Heart J. 1985 Jul; 110(1 Pt 1):17-24.
    View in: PubMed
    Score: 0.005
  183. Torres V, Flowers D, Somberg JC. The arrhythmogenicity of antiarrhythmic agents. Am Heart J. 1985 May; 109(5 Pt 1):1090-7.
    View in: PubMed
    Score: 0.005
  184. Miura DS, Keren G, Torres V, Butler B, Aogaichi K, Somberg JC. Antiarrhythmic effects of cibenzoline. Am Heart J. 1985 Apr; 109(4):827-33.
    View in: PubMed
    Score: 0.005
  185. Somberg JC, Butler B, Torres V, Tepper D, Keren G, Siegel L, Jentzer J, Miura DS. Therapy for late post infarction ventricular tachycardia. Angiology. 1985 Mar; 36(3):181-90.
    View in: PubMed
    Score: 0.005
  186. Somberg J, Tepper D, Wynn J. Prolonged repolarization: a historical perspective. Am Heart J. 1985 Feb; 109(2):395-8.
    View in: PubMed
    Score: 0.005
  187. Somberg J. Antiarrhythmic drug therapy. Recent advances and current status. Cardiology. 1985; 72(5-6):329-48.
    View in: PubMed
    Score: 0.005
  188. Somberg J, Torres V, Flowers D, Miura D, Butler B, Gottlieb S. Prolongation of QT interval and antiarrhythmic action of bepridil. Am Heart J. 1985 Jan; 109(1):19-27.
    View in: PubMed
    Score: 0.005
  189. Somberg J, Butler B, Flowers D, Tepper D, Torres V. Long term lorcainide therapy guided by electrophysiology studies. Acta Cardiol. 1985; 40(6):621-36.
    View in: PubMed
    Score: 0.005
  190. Somberg J, Butler B, Flowers D, Keefe D, Torres V, Miura D. Long-term lorcainide therapy in patients with ventricular tachycardia. Am Heart J. 1985 Jan; 109(1):33-40.
    View in: PubMed
    Score: 0.005
  191. Flowers D, O'Gallagher D, Torres V, Miura D, Somberg JC. Flecainide: long-term treatment using a reduced dosing schedule. Am J Cardiol. 1985 Jan 01; 55(1):79-83.
    View in: PubMed
    Score: 0.005
  192. Torres V, Flowers D, Miura D, Somberg J. Intravenous quinidine by intermittent bolus for electrophysiologic studies in patients with ventricular tachycardia. Am Heart J. 1984 Dec; 108(6):1437-42.
    View in: PubMed
    Score: 0.005
  193. Somberg JC. New directions in antiarrhythmic drug therapy. Am J Cardiol. 1984 Aug 13; 54(4):8B-17B.
    View in: PubMed
    Score: 0.005
  194. Somberg JC, Torres V. New directions in antiarrhythmic drug therapy: the development of a promising new agent, lorcainide. Am J Cardiol. 1984 Aug 13; 54(4):1B.
    View in: PubMed
    Score: 0.005
  195. Somberg JC, Butler B, Torres V, Flowers D, Tepper D, Keefe D, Miura DS. Lorcainide therapy for the high-risk patient post myocardial infarction. Am J Cardiol. 1984 Aug 13; 54(4):37B-42B.
    View in: PubMed
    Score: 0.005
  196. Somberg JC, Butler B, Flowers D, Keefe D, Torres V, Miura D. Evaluation of lorcainide in patients with symptomatic ventricular tachycardia. Am J Cardiol. 1984 Aug 13; 54(4):43B-48B.
    View in: PubMed
    Score: 0.005
  197. Somberg JC, Butler B, Flowers D, Tepper D, Maguire W, Willens H, Keren G, Miura D. Comparison of noninvasive arrhythmia induction techniques with electrophysiologic studies and evaluation of lorcainide in patients with symptomatic ventricular tachycardia. Am J Cardiol. 1984 Aug 13; 54(4):49B-54B.
    View in: PubMed
    Score: 0.005
  198. Somberg JC, Butler B, Torres V, Flowers D, Tepper D, Wynn J, Keren G, Miura DS. Antiarrhythmic action of bethanidine. Am J Cardiol. 1984 Aug 01; 54(3):343-6.
    View in: PubMed
    Score: 0.005
  199. Somberg JC. New approaches to drug selection and serial drug testing. J Clin Pharmacol. 1984 Jul; 24(7):320-7.
    View in: PubMed
    Score: 0.005
  200. Keren G, Miura DS, Somberg JC. Pacing termination of ventricular tachycardia: influence of antiarrhythmic-slowed ectopic rate. Am Heart J. 1984 Apr; 107(4):638-43.
    View in: PubMed
    Score: 0.004
  201. Spivack C, Gottlieb S, Miura DS, Somberg JC. Flecainide toxicity. Am J Cardiol. 1984 Jan 15; 53(2):329-30.
    View in: PubMed
    Score: 0.004
  202. Wolf ME, Ranade V, Molnar J, Somberg J, Mosnaim AD. Hypercalcemia, arrhythmia, and mood stabilizers. J Clin Psychopharmacol. 2000 Apr; 20(2):260-4.
    View in: PubMed
    Score: 0.003
  203. Wolf ME, Moffat M, Ranade V, Somberg JC, Lehrer E, Mosnaim AD. Lithium, hypercalcemia, and arrhythmia. J Clin Psychopharmacol. 1998 Oct; 18(5):420-3.
    View in: PubMed
    Score: 0.003
  204. Schulze-Bahr E, Wang Q, Wedekind H, Haverkamp W, Chen Q, Sun Y, Rubie C, Hördt M, Towbin JA, Borggrefe M, Assmann G, Qu X, Somberg JC, Breithardt G, Oberti C, Funke H. KCNE1 mutations cause jervell and Lange-Nielsen syndrome. Nat Genet. 1997 Nov; 17(3):267-8.
    View in: PubMed
    Score: 0.003
  205. Martyn R, Somberg JC, Kerin NZ. Proarrhythmia of nonantiarrhythmic drugs. Am Heart J. 1993 Jul; 126(1):201-5.
    View in: PubMed
    Score: 0.002
  206. Wyndham CR, Pratt CM, Mann DE, Winkle RA, Somberg J, de Maria AN, Josephson ME. Electrophysiology of Ethmozine (moricizine HCl) for ventricular tachycardia. Am J Cardiol. 1987 Oct 16; 60(11):67F-72F.
    View in: PubMed
    Score: 0.001
  207. Steinberg JS, Katz RJ, Somberg JC, Keefe D, Laddu AR, Burge J. Safety and efficacy of flestolol, a new ultrashort-acting beta-adrenergic blocking agent, for supraventricular tachyarrhythmias. Am J Cardiol. 1986 Nov 01; 58(10):1005-8.
    View in: PubMed
    Score: 0.001
  208. Anderson JL, Askins JC, Gilbert EM, Miller RH, Keefe DL, Somberg JC, Freedman RA, Haft LR, Mason JW, Lessem JN. Multicenter trial of sotalol for suppression of frequent, complex ventricular arrhythmias: a double-blind, randomized, placebo-controlled evaluation of two doses. J Am Coll Cardiol. 1986 Oct; 8(4):752-62.
    View in: PubMed
    Score: 0.001
  209. Morganroth J, Somberg JC, Pool PE, Hsu PH, Lee IK, Durkee J, Salerno DM. Comparative study of encainide and quinidine in the treatment of ventricular arrhythmias. J Am Coll Cardiol. 1986 Jan; 7(1):9-16.
    View in: PubMed
    Score: 0.001
  210. Brazzell RK, Colburn WA, Aogaichi K, Szuna AJ, Somberg JC, Carliner N, Heger J, Morganroth J, Winkle RA, Block P. Pharmacokinetics of oral cibenzoline in arrhythmia patients. Clin Pharmacokinet. 1985 Mar-Apr; 10(2):178-86.
    View in: PubMed
    Score: 0.001
  211. Brazzell RK, Aogaichi K, Heger JJ, Somberg JC, Carliner NH, Morganroth J. Cibenzoline plasma concentration and antiarrhythmic effect. Clin Pharmacol Ther. 1984 Mar; 35(3):307-16.
    View in: PubMed
    Score: 0.001
  212. Cagin NA, Benda R, Somberg J, Levitt B. Refractory heart failure. Comparison of time course of action of sublingual nitroglycerin and isosorbide dinitrate, oral or sublingual. N Y State J Med. 1978 May; 78(6):888-9.
    View in: PubMed
    Score: 0.001
  213. Levitt B, Cagin N, Kleid J, Somberg J, Gillis R. Role of the nervous system in the genesis of cardiac rhythm disorders. Am J Cardiol. 1976 Jun; 37(7):1111-3.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.